October 25, 2018Open Access
BEtablocker Treatment After acute Myocardial Infarction in revascularized patients without reduced left ventricular ejection fraction (BETAMI): Rationale and design of a prospective, randomized, open, blinded end point study
Structured PICO
Does beta-blocker treatment improve outcomes in revascularized patients following acute myocardial infarction without reduced left ventricular ejection fraction?
P
Population
Revascularized patients following acute myocardial infarction without reduced left ventricular ejection fraction
I
Intervention
Beta-blockers
The BETAMI trial is designed to evaluate the clinical benefit of beta-blocker therapy in revascularized post-myocardial infarction patients with preserved ejection fraction.
Abstract
The results from the BETAMI trial may have the potential of changing current clinical practice for treatment with β-blockers following MI in patients without reduced LVEF. EudraCT number 2018-000590-75.
Cite This Study
Munkhaugen et al. (Thu,) studied this question.